Monitor next quarter for sustained TMTT growth and margin expansion, as raised guidance and strong TAVR/TMTT momentum signal continued outperformance.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 24 $84.10entry
- T+1 · 7mo ago −1.07%α −1.23% · $83.20
- T+5 · 7mo ago −0.71%α −1.62% · $83.50
- T+20 · 6mo ago −1.07%α −5.09% · $83.20
- T+60 · 4mo ago +1.07%α −2.87% · $85.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Edwards Lifesciences reported strong Q1 2026 results with sales up 16.7% to $1.65B and adjusted EPS of $0.78, beating consensus by $0.05. The company raised full-year 2026 guidance for sales growth to 9-11% (from 8-10%) and adjusted EPS to $2.95-$3.05 (from $2.90-$3.05), citing strong TAVR and TMTT momentum and clinical catalysts.
Key Financial Metrics
Key Facts
- Q1 sales grew 16.7% YoY to $1.65B, constant currency growth of 12.7%
- Q1 adjusted EPS was $0.78, beating consensus of $0.73
- Raised full-year 2026 constant currency sales growth guidance to 9-11% (from 8-10%)
- Raised full-year 2026 adjusted EPS guidance midpoint to $2.95-$3.05 (from $2.90-$3.05)
- Completed $500M accelerated share repurchase
Financial Impact
$0.05 EPS beat and raised full-year guidance
Risk Factors
- Increased guidance raises bar for future quarters
- TMTT growth may face competitive pressures
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001099800-26-000021 |
| Document: ew-20260423.htm | 0001099800-26-000021 |
| Document: 0001099800-26-000021-index-headers.html | 0001099800-26-000021 |
| Document: 0001099800-26-000021-index.html | 0001099800-26-000021 |
| Document: 0001099800-26-000021.txt | 0001099800-26-000021 |
| 8-K Data (Synthetic) | 0001099800-26-000021 |
Track record
27 reports on EW
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago Insider Cluster Neutral 3/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $100.82 to $105.80 Now $107.11 +6.24% ▲ +4.94% +1.65% vs SPY
- Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $94.44 to $100.82 Now $107.11 +13.42% ▲ +6.76% +11.48% vs SPY
- Aug 31, 202611w ago Insider Cluster Neutral 2/10 Entry $90.74 to $86.18 Now $107.11 +18.04% ▼ −5.03% −5.11% vs SPY
- Aug 28, 202611w ago Insider Cluster Neutral 2/10 Entry $90.75 to $86.72 Now $107.11 +18.03% ▼ −4.44% −4.30% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers